Discovering molecular signatures that enable early cancer detection through blood, tissue, and liquid biopsy analysis
The Canary Center at Stanford is at the forefront of biomarker discovery for early cancer detection. Our researchers, led by experts like Richard Kimura, are developing blood-based tests and multi-cancer screening approaches that can detect cancer before symptoms appear, when treatment is most effective.
From protein markers to circulating tumor DNA, our comprehensive biomarker program spans the full spectrum of molecular detection methods, with several discoveries already advancing to clinical trials and commercial development.
Leading our biomarker research program, Dr. Kimura focuses on developing blood-based detection methods and multi-cancer screening trials that can identify multiple cancer types from a single blood draw.
"Biomarkers are like biological fingerprints that show the earliest signs of cancer development, enabling intervention when cure rates are highest."
Detecting cancer DNA fragments in blood samples, enabling non-invasive monitoring of tumor presence, evolution, and treatment response.
Identifying specific proteins like HE4 for ovarian cancer and CA-19-9 for pancreatic cancer that indicate early-stage disease presence.
Analyzing metabolic changes in blood and urine that occur as cancer cells alter normal cellular processes and energy production.
Studying tiny vesicles released by cancer cells that carry molecular information about the tumor, providing insights into cancer type and stage.
Validated HE4 biomarker for ovarian cancer, now used clinically worldwide
Discovered ovarian cancer gene fusion advancing molecular understanding
Discovered biomarker attracting significant industry licensing interest
Developing panel detecting 5+ cancer types from single blood draw
Large-scale clinical trial testing blood-based biomarker panels that can simultaneously screen for breast, lung, ovarian, pancreatic, and prostate cancers.
Creating non-invasive tests using blood, urine, and other body fluids to detect cancer DNA, proteins, and cells without need for tissue biopsy.
Using machine learning to identify complex biomarker patterns that human analysis might miss, improving detection accuracy and reducing false positives.
Developing rapid, affordable biomarker tests that can be performed in doctor's offices or resource-limited settings, expanding access to early detection.
Our biomarker discoveries follow a rigorous path from initial discovery to clinical implementation:
Identify candidate biomarkers
Test in patient samples
Large-scale testing
Clinical practice adoption
Help us develop the next generation of blood tests that can detect cancer early and save lives.